Literature DB >> 25407841

Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness?

Katelijne van de Vooren1, Alessandro Curto, Livio Garattini.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25407841     DOI： 10.1007/s10198-014-0653-x

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN： 1618-7598


× No keyword cloud information.
  14 in total

1.  The diffusion of health economics knowledge in Europe : The EURONHEED (European Network of Health Economics Evaluation Database) project.

Authors:  Gérard de Pouvourville; Philippe Ulmann; John Nixon; Stéphanie Boulenger; Julie Glanville; Michael Drummond
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

2.  Systematic reviews of economic evaluations: utility or futility?

Authors:  Rob Anderson
Journal:  Health Econ       Date:  2010-03       Impact factor: 3.046

3.  Tendering and value-based pricing: lessons from Italy on human papilloma virus vaccines.

Authors:  Livio Garattini; Katelijne Van de Vooren; Nick Freemantle
Journal:  J R Soc Med       Date:  2014-01       Impact factor: 5.344

4.  Hepatitis C: a new direction, but an old story?

Authors:  Christian Gluud; Ronald Koretz; Kurinchi Gurusamy
Journal:  Lancet       Date:  2014-06-21       Impact factor: 79.321

5.  Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.

Authors:  Antonio Blázquez-Pérez; Ramón San Miguel; Javier Mar
Journal:  Pharmacoeconomics       Date:  2013-10       Impact factor: 4.981

Review 6.  A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel.

Authors:  Markus Cornberg; Homie A Razavi; Alfredo Alberti; Enos Bernasconi; Maria Buti; Curtis Cooper; Olav Dalgard; John F Dillion; Robert Flisiak; Xavier Forns; Sona Frankova; Adrian Goldis; Ioannis Goulis; Waldemar Halota; Bela Hunyady; Martin Lagging; Angela Largen; Michael Makara; Spilios Manolakopoulos; Patrick Marcellin; Rui T Marinho; Stanislas Pol; Thierry Poynard; Massimo Puoti; Olga Sagalova; Scott Sibbel; Krzysztof Simon; Carolyn Wallace; Kendra Young; Cihan Yurdaydin; Eli Zuckerman; Francesco Negro; Stefan Zeuzem
Journal:  Liver Int       Date:  2011-07       Impact factor: 5.828

7.  Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C.

Authors:  Calogero Cammà; Salvatore Petta; Marco Enea; Raffaele Bruno; Fabrizio Bronte; Vincenza Capursi; Americo Cicchetti; Giorgio L Colombo; Vito Di Marco; Antonio Gasbarrini; Antonio Craxì
Journal:  Hepatology       Date:  2012-07-12       Impact factor: 17.425

8.  Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.

Authors:  Calogero Cammà; Salvatore Petta; Giuseppe Cabibbo; Matteo Ruggeri; Marco Enea; Raffaele Bruno; Vincenza Capursi; Antonio Gasbarrini; Alfredo Alberti; Antonio Craxì
Journal:  J Hepatol       Date:  2013-05-23       Impact factor: 25.083

9.  Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.

Authors:  Sandrine Cure; Florence Bianic; Sandra Gavart; Steve Curtis; Seina Lee; Geoffrey Dusheiko
Journal:  J Med Econ       Date:  2013-11-21       Impact factor: 2.448

10.  Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.

Authors:  Sandrine Cure; Florence Bianic; Sandra Gavart; Steve Curtis; Seina Lee; Geoffrey Dusheiko
Journal:  J Med Econ       Date:  2013-11-18       Impact factor: 2.448
View more
  5 in total

1.  Dutch guidelines for economic evaluation: 'from good to better' in theory but further away from pharmaceuticals in practice?

Authors:  Livio Garattini; Anna Padula
Journal:  J R Soc Med       Date:  2017-01-24       Impact factor: 5.344

2.  Abstracts from the 3rd International PPRI Conference, October 12-13, 2015, Vienna, Austria.

Authors: 
Journal:  J Pharm Policy Pract       Date:  2015-10-05

3.  Incremental cost-effectiveness pharmacoeconomic assessment of hepatitis C virus therapy: an approach for less wealthy members of the common market.

Authors:  Diana Mance; Davor Mance; Dinko Vitezić
Journal:  Croat Med J       Date:  2016-12-31       Impact factor: 1.351

4.  Chronic Hepatitis C-Related Cirrhosis Hospitalization Cost Analysis in Bulgaria.

Authors:  Maria Dimitrova; Kaloyan Pavlov; Konstantin Mitov; Jordan Genov; Guenka Ivanova Petrova
Journal:  Front Med (Lausanne)       Date:  2017-08-07

5.  Drug Pricing Evolution in Hepatitis C.

Authors:  Nathalie Vernaz; François Girardin; Nicolas Goossens; Urs Brügger; Marco Riguzzi; Arnaud Perrier; Francesco Negro
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.